611 W. Union Street
Benson, AZ 85602
(520) 586-0800

member support line
M-F 5pm-8pm
24/7 weekends/holidays

AzCH Nurse Assist Line


611 W. Union Street
Benson, AZ 85602
(520) 586-0800

AzCH Nurse Assist Line


powered by centersite dot net
Medical Disorders
Basic InformationLookupsLatest News
New Hormonal Pill May Boost Outcomes for Older Breast Cancer PatientsHad COVID? Getting Vaccinated Strengthens Your Antibodies to New VariantsU.S. to Pump $400 Million Into Vaccination Programs for Other CountriesPandemic Sent Americans' Blood Pressure Numbers SkywardWere Cancer Patients Neglected in U.S. COVID Vaccine Rollout?Young People Recover Quickly From Rare Heart Side Effect of COVID VaccineMore Evidence That Pandemic Delayed Cancer DiagnosesHigh Heart Rate Linked to Dementia RiskCOVID Vaccine, Testing Demand Overwhelming PharmaciesOmicron Spreading Through Africa Twice as Fast as Delta DidWith Holidays Ahead, COVID Boosters a Must for People With Weak Immune SystemsKeep Your Holidays Allergy-Free This YearDo Immune-Based Cancer Drugs Work Better in Men?Gene Found in Amish Helps Protect Their HeartsOmicron May Overcome Prior COVID InfectionWindy Days Are Safer Days When It Comes to COVID-19Most Vaccinated Adults Plan to Get Boosters: PollStudy Finds Delta Somewhat Resistant to Vaccines — What About Omicron?Is the Mumps Vaccine Becoming Less Effective?Vaping Can Trigger Gene Changes in Cells: StudyPfizer or Moderna? Head-to-Head Study Shows One Shot Has an EdgeSurvivors of Severe COVID Face Doubled Risk for Death a Year LaterKids With Uncontrolled Asthma at Higher Odds for Severe COVID-19Nearly 7% of U.S. Kids Have Had a Head Injury or ConcussionFirst U.S. Omicron Case Reported in California'Ultra-Processed' Foods Up Odds for a Second Heart Attack or StrokeCDC to Toughen COVID Testing for International TravelersAHA News: Irregular Heartbeat Risk Linked to Frequent Alcohol Use in People Under 40Certain Blood Thinners Can Raise Risk of 'Delayed' Bleeding After Head InjuryFDA Panel Gives Support to Merck's COVID Antiviral PillLong-Haul COVID Can Include Chronic Fatigue: StudyVaccines, Boosters Should Protect Against Severe COVID, Even With Omicron: FauciPfizer to Seek FDA Approval of Boosters for Teens Ages 16-17Regeneron Says Its Antibody Cocktail Likely Weakened by Omicron VariantCOVID May Trigger Heart Condition in Young AthletesMany People With High Blood Pressure May Take a Drug That Worsens It: StudyBiden Pushes Vaccines, Masks as Best Defense Against Omicron VariantHow Easily Can Singing Spread COVID-19?New Insights Into What Might Drive Parkinson's DiseaseHot Days Can Send Even Younger Folks to the ERRed Light in Morning May Protect Fading Eyesight: StudyMerck's COVID Pill Appears Effective, But May Pose Pregnancy Risks: FDAVaccine Makers Already Testing Their Shots Against Omicron VariantWhat Experts Know About the Omicron 'Variant of Concern'Gout Drug Colchicine Won't Help Fight COVID-19What You Need to Know About Stomach CancerFetal Infection With COVID-19 Possible, But UnlikelyCOVID Protection Wanes After 2 Doses of Pfizer Vaccine: StudyRural Hospitals' ERs Just as Effective as Urban Ones: Study1 in 5 Avoided Health Care During Pandemic, Study Finds
Questions and AnswersLinksBook Reviews
Related Topics

Men's Health
Women's Health

Targeted High-Dose Radiation Helps Fight Advanced Lung Cancer

HealthDay News
by By Amy Norton HealthDay Reporter
Updated: Oct 26th 2021

new article illustration

TUESDAY, Oct. 26, 2021 (HealthDay News) -- High-dose radiation therapy may stall tumor growth in patients with advanced lung cancer who are not fully responding to drug therapies, a preliminary study suggests.

The study involved patients whose lung cancer was considered "oligoprogressive." That means the cancer had spread to other sites in the body, and the patients were having a mixed response to standard systemic treatments — including targeted drugs, immune system therapies and chemotherapy.

Essentially, the treatments were successfully suppressing growth in some of those distant tumors, but not others.

In the trial, the researchers found that applying high-dose radiation to those drug-resistant sites extended patients' progression-free survival — the amount of time they remained stable.

Overall, patients who received radiation showed no cancer progression for a median of 44 weeks (which means half remained progression-free longer, and half for a shorter period).

That was nearly five times longer than the median for patients given standard care, at 9 weeks.

The findings suggest the radiation technique may give these patients "more mileage" out of their systemic drug therapies, said lead researcher Dr. C. Jillian Tsai, a radiation oncologist at Memorial Sloan Kettering Cancer Center in New York City.

Doctors have been occasionally using the approach in practice, on a case-by-case basis, according to Tsai. Sometimes a patient is doing well on systemic therapy but just a few lesions are no longer responding to the treatment, so doctors may try targeted radiation therapy to control those growths.

Until recently, though, the tactic had not been tested in clinical trials. Three such studies are now ongoing, Tsai said.

More evidence is needed before the approach can become the standard of care, said Dr. Steven Chmura, a radiation oncologist at the University of Chicago who was not involved in the research.

"This is the first study to test this approach formally, asking if we can extend the use of a systemic agent when it's working well in most of the body and only failing in a few spots," Chmura said.

"A phase 3 trial is needed to really change the standard of care and clinical guidelines," he said, referring to the final phase in clinical testing of a new therapy.

Tsai presented the findings Sunday at the annual meeting of the American Society for Radiation Oncology in Chicago. Studies presented at meetings are generally considered preliminary until they are published in a peer-reviewed journal.

The trial involved 58 patients with metastatic lung cancer and 44 with metastatic breast cancer. Metastatic means the initial cancer had spread to other sites in the body. All patients had one to five lesions that were progressing despite systemic therapy.

Tsai's team randomly assigned the patients to have either stereotactic body radiation therapy (SBRT) or standard care. SBRT is a widely used technique designed to deliver precise, high doses of radiation to the cancer site and spare surrounding tissue, Tsai explained.

While lung cancer patients who received SBRT remained progression-free for a median of 44 weeks, compared to 9 weeks for those who did not undergo radiation, no such benefit was seen in breast cancer patients.

"It may be because of the different biology of the diseases," Tsai said. She noted that in breast cancer patients, the lesions treated with radiation did respond — but new ones developed.

More research is needed to fully understand the different results for breast cancer patients, Tsai said. She said her team also wants to figure out which characteristics make individual patients more likely to respond to the radiation therapy.

As for potential side effects of SBRT, they vary depending on where the radiation is given. If it's delivered to the bones, for example, it can cause a temporary pain flare-up, Tsai said. If the radiation is to the lungs, it can cause inflammation.

During the trial, eight patients given radiation had at least a moderately severe side effect.

While phase 3 trials have not been done yet, it is possible for lung cancer patients like those in this study to get radiation therapy.

Chmura said, "I think if a patient with [lung cancer] is doing well on systemic therapy but is told they are progressing in a few small spots, it would be useful for them to know this treatment option exists."

SBRT has been used for about a decade, he noted, and is widely available around the world.

More information

The American Cancer Society has more on lung cancer treatment.

SOURCES: C. Jillian Tsai, MD, PhD, radiation oncologist, and director, metastatic disease radiation oncology research, Memorial Sloan Kettering Cancer Center, New York City; Steven Chmura MD, PhD, director, clinical and translational research for radiation oncology, University of Chicago; presentation, American Society for Radiation Oncology annual meeting, Chicago, Oct. 24, 2021